Ozempic Lawsuit 2025: Rising MDL, Vision Loss Claims, and What You Need to Know

Mark Paul
Aug 19, 2025
2 min read

Introduction

The Ozempic lawsuit continues to make headlines in 2025 amid growing legal and medical scrutiny. As one of the hottest topics in health and wellness, the MDL (Multidistrict Litigation) surrounding semaglutide—marketed as Ozempic—is capturing both media attention and search engine traffic. Popular related search terms include “Ozempic lawsuit”, “NAION vision loss Ozempic”, “Ozempic gastroparesis lawsuit”, “semaglutide MDL 2025”, and “Ozempic failure to warn”.

Key Legal Milestones in 2025

1. Steady Growth of the MDL

Multidistrict litigation (MDL No. 3094) in the Eastern District of Pennsylvania has rapidly expanded. As of March, around 1,521 cases were consolidated.
By July 1, 2025, that number skyrocketed to 1,997—with projections indicating it would easily exceed 2,000 soon.

2. Vision Loss (NAION) Lawsuits Take Center Stage

NAION (Non-Arteritic Anterior Ischemic Optic Neuropathy) lawsuits involving permanent vision loss are surging—some filed outside the MDL.
Victims like a grandmother of 11 and a New Jersey resident are claiming their blindness was caused by Ozempic, citing failure to warn.
As of early August, over 20 plaintiffs have pursued NAION-related lawsuits, especially in New Jersey courts.

3. Legal Milestones & Strategy

The Rule 702 Daubert hearing (about admitting expert testimony) took place on May 14, 2025, a pivotal moment for case progression.
The legal focus now includes anticipated bellwether trials, expanding claim types (like pancreatitis), and the potential push for settlements.

4. Expanding Risks: From GI Issues to Organ Damage and Clots

While gastroparesis, intestinal blockages, and gastrointestinal injuries remain the predominant claims, new waves include pancreatitis, gallbladder disease, kidney injuries, and even blood clots (DVT).

5. Compounded Semaglutide vs. Brand Claims

Novo Nordisk is suing compounding pharmacies and telehealth providers—like Prism Aesthetics and Mochi Health—for making unapproved versions of semaglutide, claiming safety and legal violations.
A federal court confirmed its stance to uphold the FDA’s removal of Ozempic from the drug shortage list, effectively restricting compounded versions.
Despite this, some knockoff alternatives still circulate due to loopholes, drawing criticism and further litigation.